✦ LIBER ✦

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

✍ Scribed by Uwe Wagner; Andreas du Bois; Jacobus Pfisterer; Jens Huober; Sybille Loibl; Hans-Joachim Lück; Jalid Sehouli; Martina Gropp; Anne Stähle; Barbara Schmalfeldt; Werner Meier; Christian Jackisch

Book ID: 113960900
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 146 KB
Volume: 105
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2006.10.053

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

959 PUBLICATION Evaluation of gefinitib

959 PUBLICATION Evaluation of gefinitib in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane chemotherapy — results of a phase II study (ovar 2.6) of the AGO

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

A phase II trial of intraperitoneal inte

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

✍ Anda M. Vlad; Raluca A. Budiu; Diana E. Lenzner; Yun Wang; Julia A. Thaller; Kel 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 375 KB

A phase II study of capecitabine in the

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial

✍ Carmela Pisano; Alessandro Morabito; Roberto Sorio; Enrico Breda; Rossella Lauri 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 303 KB

Combined PEG liposomal doxorubicin and g

Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study

✍ E. Petru; L. Angleitner-Boubenizek; A. Reinthaller; M. Deibl; A.G. Zeimet; B. Vo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Addition of vandetanib to pegylated lipo

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

✍ Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, JÃ¶rn; Hilpert, Felix; Kur 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 162 KB

Intraperitoneal treatment with the trifu

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group

✍ K. Baumann; J. Pfisterer; P. Wimberger; N. Burchardi; C. Kurzeder; A. du Bois; S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 255 KB